Abstract
Quality of life (QoL) data from randomized trials is lacking in older patients with metastatic colorectal cancer (mCRC). In the randomized NORDIC9-study, reduced-dose combination chemotherapy S1+oxaliplatin (SOx) showed superior efficacy compared to full-dose monotherapy S1 (Teysuno). Here, we hypothesized, that treatment with reduced-dose SOx does not result in inferior QoL and physical functioning compared to treatment with full-dose S1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
